Leslie M. Shaw, Magdalena Korecka, Edward B. Lee, Katheryn A Q Cousins, Hugo Vanderstichele, Suzanne E. Schindler, Duygu Tosun, Mari L. DeMarco, Magdalena Brylska, Yang Wan, Samantha Burnham, Alexandria Sciulli, Amberley Vulaj, Thomas F. Tropea, Alice Chen-Plotkin, David A. Wolk, the Alzheimer's Disease Neuroimaging Initiative
{"title":"ADNI Biomarker Core: A review of progress since 2004 and future challenges","authors":"Leslie M. Shaw, Magdalena Korecka, Edward B. Lee, Katheryn A Q Cousins, Hugo Vanderstichele, Suzanne E. Schindler, Duygu Tosun, Mari L. DeMarco, Magdalena Brylska, Yang Wan, Samantha Burnham, Alexandria Sciulli, Amberley Vulaj, Thomas F. Tropea, Alice Chen-Plotkin, David A. Wolk, the Alzheimer's Disease Neuroimaging Initiative","doi":"10.1002/alz.14264","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> BACKGROUND</h3>\n \n <p>We describe the Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core major activities from October 2004 to March 2024, including biobanking ADNI cerebrospinal fluid (CSF), plasma, and serum biofluid samples, biofluid analyses for Alzheimer's disease (AD) biomarkers in the Biomarker Core and various non-ADNI laboratories, and continuous assessments of pre-analytics.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Validated immunoassay and mass spectrometry-based assays were performed in CSF with a shift to plasma, a more accessible biofluid, as qualified assays became available. Performance comparisons across different CSF and plasma AD biomarker measurement platforms have enriched substantially the ADNI participant database enabling method performance determinations for AD pathology detection and longitudinal assessments of disease progression.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Close collaboration with academic and industrial partners in the validation and implementation of AD biomarkers for early detection of disease pathology in treatment trials and ultimately in clinical practice is a key factor for the success of the work done in the Biomarker Core.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Describe ADNI Biomarker Core biobanking and sample distribution from 2007 to 2024.</li>\n \n <li>Discuss validated mass spectrometry and immunoassay methods for ADNI biofluid analyses.</li>\n \n <li>Review collaborations with academic and industrial partners to detect AD and progression.</li>\n \n <li>Discuss major challenges, and progress to date, for co-pathology detection.</li>\n \n <li>Implementation in the ATN scheme: co-pathology and modeling disease progression.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 1","pages":""},"PeriodicalIF":11.1000,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.14264","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14264","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
BACKGROUND
We describe the Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core major activities from October 2004 to March 2024, including biobanking ADNI cerebrospinal fluid (CSF), plasma, and serum biofluid samples, biofluid analyses for Alzheimer's disease (AD) biomarkers in the Biomarker Core and various non-ADNI laboratories, and continuous assessments of pre-analytics.
RESULTS
Validated immunoassay and mass spectrometry-based assays were performed in CSF with a shift to plasma, a more accessible biofluid, as qualified assays became available. Performance comparisons across different CSF and plasma AD biomarker measurement platforms have enriched substantially the ADNI participant database enabling method performance determinations for AD pathology detection and longitudinal assessments of disease progression.
DISCUSSION
Close collaboration with academic and industrial partners in the validation and implementation of AD biomarkers for early detection of disease pathology in treatment trials and ultimately in clinical practice is a key factor for the success of the work done in the Biomarker Core.
Highlights
Describe ADNI Biomarker Core biobanking and sample distribution from 2007 to 2024.
Discuss validated mass spectrometry and immunoassay methods for ADNI biofluid analyses.
Review collaborations with academic and industrial partners to detect AD and progression.
Discuss major challenges, and progress to date, for co-pathology detection.
Implementation in the ATN scheme: co-pathology and modeling disease progression.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
